Dose-effect study of carboplatin in ovarian cancer: A Danish Ovarian Cancer Group study

Journal of Clinical Oncology

Volumn 15, Issue 1, 1997, Pages 193-198

  Jakobsen, A ^a   Bertelsen, K ^a   Andersen, J E ^a   Havsteen, H ^a   Jakobsen, P ^a   Moeller, K A ^a   Nielsen, K ^a   Sandberg, E ^a   Stroeyer, I ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; DENMARK; FEMALE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; NAUSEA; OVARY CANCER; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0031025089     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.1.193     Document Type: Article

References (22)

1. McMillan TJ, Stephens TC, Steel GG: Clonal variation in the sensitivity of a murine mammary carcinoma to melphalan. Br J Cancer 53:753-759, 1986
2. Odaimi M, Ajani J: High-dose chemotherapy. Am J Clin Oncol 10:123-132, 1987
3. Levin L, Hryniuk WM: Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol 5:756-767, 1987
4. Kaye S, Lewis CR, Paul J, et al: Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 340:329-333, 1992
5. Ngan HY, Choo YC, Cheung M, et al: A randomized study of high-dose versus low-dose cis-platinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Hong Kong Ovarian Carcinoma Study Group. Chemotherapy 35:221-227, 1989
6. McGuire WP, Hoskins WJ, Brady MF, et al: Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 13:1589-1599, 1995
7. Colombo N, Pittelli MR, Parma G, et al: Cisplatin (P) dose intensity in advanced ovarian cancer (AOC): A randomized study of conventional dose (DC) vs dose-intense (DI) cisplatin chemotherapy. Proc Am Soc Clin Oncol 15:255, 1993 (abstr)
8. Conte PF, Bruzzone F, Carnino F, et al: High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: A randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol 14:351-356, 1996
9. Dittrich C, Obermair C, Kurtz C, et al: Prospective randomized trial of cisplatin/ carboplatin versus conventional cisplatin/ cyclophosphamide in epithelial ovarian cancer: First results of the impact of platinum dose intensity on patient outcome. Proc Am Soc Clin Oncol 15:279, 1996 (abstr)
10. Gore ME, Mainwaring PN, Macfarlane V, et al: A randomized study of high versus standard dose carboplatin in patients (pts) with advanced epithelial ovarian cancer (EOC). Proc Am Soc Clin Oncol 15:284, 1996 (abstr)
11. Jakobsen P, Steiness E, Bastholt L, et al: Multiple-dose pharmacokinetics of epirubicin at four different dose levels: Studies in patients with metastatic breast cancer. Cancer Chemother Pharmacol 28:63-68, 1991
12. Sørensen BT, Strömgren A, Jakobsen P, et al: Dose-toxicity relationship of carboplatin in combination with cyclophosphamide in ovarian cancer patients. Cancer Chemother Pharmacol 28:397-401, 1991
13. Strömgren AS, Sørensen BT, Jakobsen P, et al: A limited sampling method for estimation of the etoposide area under the curve. Cancer Chemother Pharmacol 32:226-230, 1993
14. Sørensen BT, Strömgren A, Jakobsen P, et al: A limited sampling method for estimation of the carboplatin area under the curve. Cancer Chemother Pharmacol 31:324-327, 1993
15. Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748-1756, 1989
16. Hryniuk W: The importance of dose intensity in outcome of chemotherapy, in DeVita VTJ, Hellman S, Rosenberg SA (eds): Important Advances in Oncology. Philadelphia, PA, Lippincott, 1988, pp 121-141
17. Longo DL, Duffey PL, DeVita VT Jr, et al: The calculation of actual or received dose intensity: A comparison of published methods. J Clin Oncol 9:2042-2051, 1991
18. Duncan GF, Faulkner HC, Farmen RH, et al: Liquid chromatographic procedure for the quantitative analysis of carboplatin in Beagle dog plasma ultrafiltrate. J Pharmaceut Sci 77:273-276, 1988
19. Bertelsen K, Jakobsen A, Strøyer I, et al: A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, Adriamycin, and cisplatin in advanced epithelial ovarian cancer: A Danish Ovarian Study Group trial (DACOVA). Gynecol Oncol 49:30-36, 1993
20. Hakes TB, Chalas E, Hoskins WJ, et al: Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 45:284-289, 1992
21. Repetto L, Pace M, Mammoloti S, et al: The impact of received dose intensity on the outcome of advanced ovarian cancer. Eur J Cancer 2:181-184, 1993
22. van Warmerdam LJC, Rodenhuis S, van Tellingen O, et al: Validation of a limited sampling model for carboplatin in a high-dose chemotherapy combination. Cancer Chemother Pharmacol 35:179-181, 1994